calcitonin gene related peptide medications Erenumab (Aimovig - Calcitoningene-relatedpeptidereceptor CGRP inhibitors are medications that treat (and, in some cases, prevent) migraine headaches Understanding Calcitonin Gene-Related Peptide Medications for Migraine

Calcitoningene-relatedpeptidereceptor Migraine headaches, a debilitating neurological condition affecting millions worldwide, have seen a significant advancement in treatment options with the development of calcitonin gene-related peptide medications.Gepants: Both A Preventive and An Acute Treatment for Migraine For decades, the exact role of CGRP in migraine pathophysiology remained a subject of intensive research.2025年4月22日—Calcitonin gene-related peptide (CGRP)–targeted therapiesare the first medications developed specifically for migraine prevention. However, the groundbreaking discovery of its involvement in pain transmission and vasodilation associated with migraines has paved the way for a new class of targeted therapiesCalcitonin gene-related peptide-targeted therapy in migraine. These calcitonin gene-related peptide (CGRP) inhibitors are specifically designed to address the underlying mechanisms of migraine, offering relief and prevention for many who have not found success with conventional treatments.

The journey to understanding and utilizing calcitonin gene-related peptide in migraine treatment began with extensive translational research. This led to the development of two classes of drugs that inhibit the actions of calcitonin gene-related peptide, which is implicated in migraine.Calcitonin gene-related peptide (CGRP) receptor ... These advancements have ushered in a new era in migraine management, moving beyond symptomatic relief to address the root causes. The efficacy of these calcitonin gene-related peptide (CGRP)-targeted therapies has been established, marking a pivotal moment in neurology.作者：S Barnes·2025·被引用次数：3—Calcitonin gene-related peptide (CGRP)–targeted therapiesare the first medications developed specifically for migraine prevention.

The Science Behind CGRP-Targeted Therapies

Calcitonin gene-related peptide (CGRP) is a neuropeptide found throughout the nervous system, playing a crucial role in various physiological processes, including vasodilation and pain signaling2025年3月31日—Calcitonin gene-related peptide (CGRP) inhibitorsare a migraine prophylaxis treatment for patients who have not responded to conventional migraine therapies.. In the context of migraine, elevated levels of CGRP are observed during attacks, contributing to the inflammation and pain experienced by sufferers. Calcitonin gene-related peptide medications work by blocking the action of CGRP, either by targeting the peptide itself or its receptor. This mechanism effectively interrupts the migraine cascade, providing relief and preventing future attacks.

The development of these targeted therapies represents a significant leap forward, as they are the first medications developed specifically for migraine prevention.作者：S Barnes·2025·被引用次数：3—Calcitonin gene-related peptide (CGRP)–targeted therapiesare the first medications developed specifically for migraine prevention. This focus on the underlying biology of migraine sets them apart from older treatments. While traditional acute treatments like triptans, acetaminophen, aspirin, diclofenac sodium, naproxen and ibuprofen can offer some relief, they often do not address the inflammatory and neurological processes that CGRP is involved in.

Types of Calcitonin Gene-Related Peptide Medications

Currently, there are two primary categories of calcitonin gene-related peptide medications: monoclonal antibodies (mAbs) and small molecule antagonists (gepants).

* Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies (mAbs): These are injectable medications that target either the CGRP molecule or the CGRP receptor. They are typically administered monthly or quarterly and are primarily used for migraine prevention. Examples include:

* Erenumab (Aimovig)

* Eptinezumab (Vyepti)

* Fremanezumab (Ajovy)

* Galcanezumab (Emgality)

* Eptinezumab (ALD403) is approved for prevention of migraine.

* Fremanezumab (TEV-48125) is approved for prevention of migraine.Calcitonin Gene-Related Peptide Inhibitors for Migraine ...

* Galcanezumab (LY2951742) is approved for prevention of migraine.

* Eptinezumab, fremanezumab, and galcanezumab are similar antibodies for migraines that instead bind to the CGRP molecules.Evaluation of 8 CGRP-targeted Therapy Dr | DDDT

* Calcitonin Gene-Related Peptide Receptor Antagonists (Gepants): These are oral medications that block the CGRP receptor. Gepants can be used for both acute treatment of migraine attacks and for prevention. Notable gepants include:

* Rimegepant

* Ubrogepant

* Evidence from phase III RCTs showed that rimegepant and ubrogepant were better than placebo for two key outcomes – freedom from pain and freedom from the most bothersome migraine symptom作者：JC Ray·2021·被引用次数：73—After 30 years of translational research,calcitonin gene-related peptide (CGRP) inhibitorshave emerged as a promising new tool in the prevention of migraine..

* Atogepant (Qulipta) is another oral option for preventionStrong evidence of the efficacy oftriptans, acetaminophen, aspirin, diclofenac sodium, naproxen and ibuprofenfor the acute treatment of migraines..

* Zavegepant is also available as an oral option.

* Calcitonin gene-related peptide (CGRP) receptor antagonists are medications approved for the prevention of chronic migraine.

These CGRP mAb and gepant medications have demonstrated significant efficacy in clinical trials, offering a new avenue for managing this complex condition.Calcitonin Gene‐Related Peptide Modulators – The History ...

Efficacy and Safety Profile

The introduction of calcitonin gene-related peptide (CGRP)-targeted therapies has been a game-changer for many migraine sufferers. These medications have consistently shown robust efficacy, overall good tolerability, and a good safety profile in numerous pivotal studies. They are designed to prevent or acutely treat migraines by blocking the pain pathway associated with CGRP.

For individuals who have not responded to conventional migraine therapies, calcitonin gene-related peptide (CGRP) inhibitors offer a valuable prophylaxis treatment. The effectiveness of anti-calcitonin gene-related peptide monoclonal antibodies has also been shown to relieve symptoms like vertigo and dizziness in vestibular migraine. Importantly, research indicates that erenumab, galcanezumab, ubrogepant, atogepant and zavegepant are suitable for elderly patients, though all 8 CGRP-targeted therapy drugs were not suitable for children.

Historical Context and Future Directions

The History and review of anti-calcitonin gene-related peptide (CGRP) therapies highlight the significant progress made from initial translational research to current treatment options2024年11月5日—Common Triptans available in Australia include Sumatriptan (Imitrex, Imigran), Rizatriptan (Maxalt), Eletriptan (Relpax), Zolmitriptan (Zomig) .... The understanding of calcitonin gene-related peptide and its role in migraine pathophysiology has been crucial.2025年4月22日—Calcitonin gene-related peptide (CGRP)–targeted therapiesare the first medications developed specifically for migraine prevention. While these medications represent a major advancement, research continues to explore new ways to modulate calcitonin gene-related peptide activity and its receptor. The development of calcitonin gene-related peptide receptor antagonists and monoclonal antibodies has revolutionized migraine care, offering hope and improved quality of life for countless individuals. The ongoing study of calcitonin gene-related peptide is vital for further refining existing treatments and discovering even more effective therapies for migraine.